Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
2000 , .
As research continues, D-allulose may emerge as a valuable tool in the fight against obesity and related diseases
And women on GLP-1 medications face a specific nutritional risk profile: reduced iron intake from smaller meal volumes compounding pre-existing deficiency, which is more common in menstruating women to begin with (Urbina et al., 2026, 480,825 adults)
Whilst these medicines offer significant therapeutic benefits, taste disturbances such as metallic, bitter, or unpleasant sensations may occur, often linked to delayed gastric emptying and gastrointestinal effects
Randomized trialSemaglutide evidence2021 Once-Weekly Semaglutide in Adults with Overweight or Obesity Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context
They also modulate insulin secretion in a glucose-dependent manner, improving glycemic control without significantly increasing hypoglycemia risk in non-diabetic patients
US$ 24.33
US$ 24.60
US$ 26.29
US$ 20.64
US$ 22.95
US$ 22.67
